Journal
JOURNAL OF HEPATOLOGY
Volume 75, Issue 6, Pages 1301-1311Publisher
ELSEVIER
DOI: 10.1016/j.jhep.2021.07.003
Keywords
Fibrosis; HCV; DAA; Extracellular vesicles; miRNAs; Proteomics; nLC-MS/MS; DIAPH1; miR204-5p; miR181a-5p; miR93-5p; miR143-3p
Categories
Funding
- EXO-DAA project [L.R. Lazio 13/08]
- Ministry for Health of Italy (Ricerca Corrente)
- Sapienza University of Rome [RG11916B6A9C42C7]
- Italian Ministry of Health Ricerca Finalizzata [GR-2013-02359524]
- Consorzio Interuniversitario Biotecnologie: fellowship
Ask authors/readers for more resources
The study focused on analyzing extracellular vesicles (EVs) from healthy donors and HCV-infected patients before and after DAA treatment, revealing significant differences in miRNA and protein cargos between the two groups. The findings suggest that modifications in EVs could play a role in long-term liver disease progression in patients with HCV despite achieving virological cure.
Background & Aims: Patients with HCV who achieve a sustained virological response (SVR) on direct-acting antiviral (DAA) therapy still need to be monitored for signs of liver disease progression. To this end, the identification of both disease biomarkers and therapeutic targets is necessary. Methods: Extracellular vesicles (EVs) purified from plasma of 15 healthy donors (HDs), and 16 HCV-infected patients before (T0) and after (T6) DAA treatment were utilized for functional and miRNA cargo analysis. EVs purified from plasma of 17 HDs and 23 HCV-infected patients (T0 and T6) were employed for proteomic and western blot analyses. Functional analysis in LX2 cells measured fibrotic markers (mRNAs and proteins) in response to EVs. Structural analysis was performed by qPCR, label-free liquid chromatography-mass spectrometry and western blot. Results: On the basis of observations indicating functional differences (i.e. modulation of FN-1, ACTA2, Smad2/3 phosphorylation, collagen deposition) of plasma-derived EVs from HDs, T0 and T6, we performed structural analysis of EVs. We found consistent differences in terms of both miRNA and protein cargos: (i) antifibrogenic miR204-5p, miR181a-5p, miR143-3p, miR93-5p and miR122-5p were statistically underrepresented in T0 EVs compared to HD EVs, while miR204-5p and miR143-3p were statistically underrepresented in T6 EVs compared to HD EVs (p <0.05); (ii) proteomic analysis highlighted, in both T0 and T6, the modulation of several proteins with respect to HDs; among them, the fibrogenic protein DIAPH1 was upregulated (Log(2) fold change of 4.4). Conclusions: Taken together, these results highlight structural EV modifications that are conceivably causal for long-term liver disease progression in patients with HCV despite DAA-mediated SVR. Lay summary: Direct-acting antivirals lead to virological cure in the majority of patients with chronic hepatitis C virus infection. However, the risk of liver disease progression or complications in patients with fibrosis and cirrhosis remains in some patients even after virological cure. Herein, we show that extracellular vesicle modifications could be linked to long-term liver disease progression in patients who have achieved virological cure; these modifications could potentially be used as biomarkers or treatment targets in such patients. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available